quinazolines has been researched along with Anxiety in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (14.29) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Azevedo, H; Ferreira, M; Mascarello, A; Osten, P; Werneck Guimarães, CR | 1 |
| Agarwal, RK; Das, D; Gajbhiye, A; Mishra, S; Patil, S; Sahu, A; Verma, E | 1 |
| Berkel, TDM; Pandey, SC; Sakharkar, AJ; Teppen, T; Zhang, H | 1 |
| Lagos, P; Scorza, C; Torterolo, P; Urbanavicius, J | 1 |
| Bi, LL; Chen, YH; Gao, TM; Geng, F; Li, XW; Liu, F; Liu, JH; Lu, YS; Mei, L; Sun, XD; Wang, J; Zhang, J; Zhang, M | 1 |
| Buiting, HM; de Kanter, W; Linn, SC; Smorenburg, CH | 1 |
| Bogovyk, R; Fedoriuk, M; Holmes, GL; Isaev, D; Isaeva, E; Krishtal, O; Lunko, O | 1 |
| Besson, V; Büki, A; Bukovics, P; Dóczi, T; Hernádi, I; Kövesdi, E; Lückl, J; Nyirádi, J; Pál, J; Sümegi, B | 1 |
| Farook, JM; Lee, L; Moochhala, SM; Wang, Q; Wong, PT; Zhu, YZ | 1 |
| Djahanguiri, B; Massoudi, R; Rezayat, M; Roohbakhsh, A; Zarrindast, MR | 1 |
| Allison, C; Pratt, JA | 1 |
| Chaki, S; Sekiguchi, Y; Semple, G; Thomsen, W; Tran, TA; Yamada, H; Yamaguchi, J | 1 |
| Imaizumi, M; Miyazaki, S; Onodera, K | 1 |
| Comet, D; Grange, JC; Lukacs, B; Thibault, P | 1 |
2 review(s) available for quinazolines and Anxiety
| Article | Year |
|---|---|
[Living with incurable cancer].
Topics: Aged; Anxiety; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Depression; Emotions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Psychotherapy; Quality of Life; Quinazolines | 2016 |
ATC0175: an orally active melanin-concentrating hormone receptor 1 antagonist for the potential treatment of depression and anxiety.
Topics: Animals; Anxiety; Cyclohexylamines; Depression; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Immobility Response, Tonic; Maze Learning; Motor Activity; Quinazolines; Receptors, Somatostatin | 2005 |
12 other study(ies) available for quinazolines and Anxiety
| Article | Year |
|---|---|
The serotonergic and alpha-1 adrenergic receptor modulator ACH-000029 ameliorates anxiety-like behavior in a post-traumatic stress disorder model.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Anti-Anxiety Agents; Anxiety; Brain Chemistry; Genes, fos; Male; Mice; Mice, Inbred C57BL; Piperazines; Prazosin; Quinazolines; Receptors, Adrenergic, alpha-1; Serotonin Agents; Social Interaction; Stress Disorders, Post-Traumatic; Stress, Psychological | 2020 |
Electronegativity in Substituted-4(H)-quinazolinones Causes Anxiolysis without a Sedative-hypnotic Adverse Reaction in Female Wistar Rats.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Depression; Female; Hypnotics and Sedatives; Lethal Dose 50; Motor Activity; No-Observed-Adverse-Effect Level; Pentobarbital; Quinazolines; Rats; Rats, Wistar; Sleep; Swimming | 2020 |
Essential Role of Histone Methyltransferase G9a in Rapid Tolerance to the Anxiolytic Effects of Ethanol.
Topics: Amygdala; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Disease Models, Animal; Drug Tolerance; Epigenesis, Genetic; Ethanol; Gene Expression Regulation; Histone-Lysine N-Methyltransferase; Male; Neuropeptide Y; Quinazolines; Rats; Rats, Sprague-Dawley | 2019 |
Prodepressive effect induced by microinjections of MCH into the dorsal raphe: time course, dose dependence, effects on anxiety-related behaviors, and reversion by nortriptyline.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Anxiety; Behavior, Animal; Central Nervous System Depressants; Cyclohexylamines; Depression; Dorsal Raphe Nucleus; Dose-Response Relationship, Drug; Hypothalamic Hormones; Male; Maze Learning; Melanins; Microinjections; Motor Activity; Neuropsychological Tests; Nortriptyline; Pituitary Hormones; Quinazolines; Rats, Wistar; Receptors, Somatostatin; Time Factors | 2014 |
Amygdala NRG1-ErbB4 is critical for the modulation of anxiety-like behaviors.
Topics: Amygdala; Animals; Anxiety; Disease Models, Animal; Enzyme Inhibitors; Exploratory Behavior; Feeding Behavior; gamma-Aminobutyric Acid; Gene Expression Regulation; Glutamate Decarboxylase; GPI-Linked Proteins; In Vitro Techniques; Male; Maze Learning; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myelin Proteins; Nogo Receptor 1; Pyrimidines; Quinazolines; Reaction Time; Receptor, ErbB-4; Receptors, Cell Surface; Signal Transduction; Tyrphostins | 2015 |
Effects of protease-activated receptor 1 inhibition on anxiety and fear following status epilepticus.
Topics: Animals; Anxiety; Epilepsy, Temporal Lobe; Fear; Male; Pilocarpine; Pyrroles; Quinazolines; Rats; Rats, Wistar; Receptor, PAR-1; Status Epilepticus | 2017 |
A novel PARP inhibitor L-2286 in a rat model of impact acceleration head injury: an immunohistochemical and behavioral study.
Topics: Animals; Anxiety; Axons; Behavior, Animal; Brain Injuries; Disease Models, Animal; Enzyme Inhibitors; Immunohistochemistry; Infusions, Intraventricular; Male; Neuroprotective Agents; Piperidines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Quinazolines; Rats; Rats, Wistar | 2010 |
Analysis of strain difference in behavior to Cholecystokinin (CCK) receptor mediated drugs in PVG hooded and Sprague-Dawley rats using elevated plus-maze test apparatus.
Topics: Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Benzodiazepines; Brain; Chemokines; Chemokines, CC; Cholecystokinin; Male; Maze Learning; Proglumide; Pyrazoles; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Species Specificity; Tetragastrin | 2004 |
Cholecystokinin and GABA interaction in the dorsal hippocampus of rats in the elevated plus-maze test of anxiety.
Topics: Animals; Anxiety; Bicuculline; Cholecystokinin; Dose-Response Relationship, Drug; GABA Antagonists; gamma-Aminobutyric Acid; Hippocampus; Male; Microinjections; Quinazolines; Quinazolinones; Rats; Rats, Wistar; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Stereotaxic Techniques | 2005 |
Differential effects of two chronic diazepam treatment regimes on withdrawal anxiety and AMPA receptor characteristics.
Topics: Animals; Anxiety; Autoradiography; Diazepam; Excitatory Amino Acid Antagonists; Hypnotics and Sedatives; Imidazoles; In Situ Hybridization; Injections, Intraperitoneal; Injections, Subcutaneous; Male; Oligonucleotide Probes; Quinazolines; Rats; Rats, Long-Evans; Receptors, AMPA; RNA, Messenger; Substance Withdrawal Syndrome | 2006 |
Effects of a non-xanthine adenosine antagonist, CGS 15943, and a phosphodiesterase inhibitor, Ro 20-1724, in a light/dark test in mice.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Adenosine; Animals; Anxiety; Darkness; Light; Male; Mice; Mice, Inbred ICR; Motor Activity; Phosphodiesterase Inhibitors; Quinazolines; Triazoles | 1994 |
Construction and validation of a short-form benign prostatic hypertrophy health-related quality-of-life questionnaire. BPH Group in General Practice.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Anxiety; Case-Control Studies; Cohort Studies; Cross-Sectional Studies; Humans; Longitudinal Studies; Male; Middle Aged; Perception; Prostatic Hyperplasia; Psychometrics; Quality of Life; Quinazolines; Sensitivity and Specificity; Sexual Behavior; Surveys and Questionnaires; Urination Disorders | 1997 |